Resultado de búsqueda
28 de jun. de 2024 · In this post hoc analysis of a randomised controlled trial, the aim is to investigate the heterogeneity in vilobelimab’s treatment effect and adverse events in critically ill COVID-19 patients. Routinely measured clinical data was used to identify classes and to assign to known subtypes.
2 de jul. de 2024 · Celecoxib-tramadol co-crystal was associated with reduced rescue medication use and an acceptable tolerability profile compared with tramadol or celecoxib alone in adults with acute, moderate-to-severe, postoperative pain.
16 de jun. de 2024 · Linvoseltamab (200 mg) induced 71% overall response rate with 50% rate of complete response (CR) or better (≥CR), and a median duration of response of 29.4 months. The most common adverse event was cytokine release syndrome in 46% of patients (35.0% grade 1, 10.3% grade 2, 0.9% grade 3).
11 de jun. de 2024 · Common adverse events (AEs) include fatigue, nausea and vomiting, and anemia. Nuanced AE management guidance for these combinations is lacking. The panel objective was to develop expert consensus on AE management in patients with mPC treated with the combination PARPi + NHT.
15 de jun. de 2024 · The most common grade 3–4 treatment-emergent adverse event was neutropenia in 32 (25%) of 128 patients. Grade 1–2 cytokine release syndrome was reported in 83 (65%) of 128 patients; grade 3 cytokine release syndrome was reported in two (2%).
12 de jun. de 2024 · A panel of experts developed guidelines for adverse event (AE) management in patients with metastatic prostate cancer treated with a combination of poly-ADP ribose polymerase inhibitors and novel hormonal therapy.
13 de jun. de 2024 · Treatment-emergent adverse events are listed in Table 3. The most common adverse event was diarrhea, with 53% experiencing grade 1–2, 33% facing grade 3, and 6.7% encountering grade 4 diarrhea.
